Novo Nordisk's Court Setback, CagriSema Subgroup Data and Buyback Ledger All Defer to November Earnings
Published on 10/27/2026 at 03:10 | Editorial boerse-global.de
Novo Nordisk shareholders got three distinct pieces of news this cycle — a legal ruling, a clinical readout and a capital-return update — and none of them settles the question that matters most: how the business is actually performing. That answer is scheduled for 4 November 2026, when the Danish drugmaker reports third-quarter results before the market opens.
A procedural loss, not a verdict on the merits
US District Judge Zahid Quraishi on Tuesday declined Novo Nordisk's request for a preliminary injunction against advertising by Eli Lilly for its weight-loss medicines, Reuters reported. The company had sought to halt the campaigns through emergency relief; that immediate objective failed.
What the ruling does not do is resolve the central dispute. The court made no finding on whether the advertisements were misleading, so the decision neither validates Lilly's marketing claims nor delivers a final rejection of Novo Nordisk's allegations. The underlying lawsuit proceeds.
For investors, the distinction is everything. This is a setback at an interim procedural stage, not a definitive loss in the advertising fight. Anyone reading the headline as a verdict on the competing claims is drawing a conclusion the ruling does not support.
CagriSema's 25% figure comes with a label
Separately, Novo Nordisk published on 20 October a post-hoc analysis of the REDEFINE 1 trial of CagriSema. Among women with overweight or obesity, treatment was associated with an average weight loss of 25% after 68 weeks, against 3% on placebo, according to Reuters coverage roughly a week earlier.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The caveats are as important as the number. This is a retrospective look at one subgroup — women — and the company explicitly states it should not be equated with the trial's primary result. The findings cannot be read as the outcome for all participants, and clinical data of any kind is not the same thing as a regulatory approval.
Awiqli clears the FDA for children ten and up
On the regulatory front, the US Food and Drug Administration has approved Awiqli as a supplement to diet and exercise to improve blood-sugar control in children aged ten and older with type 2 diabetes. The agency said it is the first once-weekly insulin for pediatric patients with the condition.
A concrete approval, yes — but the economic question is separate. What the label permits and what the product actually earns in the market are two different matters, and the regulatory green light says nothing about the second.
Buybacks: real money, no read on operations
Alongside these developments, Novo Nordisk continues to repurchase its own stock. The company counts 40,274,179 B shares bought back, at a cost of DKK 11,187,348,102. Its total holding of treasury B shares equals 1.2% of share capital, according to company figures.
That is a tangible deployment of corporate funds, but it stands apart from the product news. A buyback documents how capital is being used; it offers no evidence about revenue or profit trends.
What 4 November can and cannot settle
Strip away the individual headlines and the pattern is consistent: a pediatric insulin approval, additional CagriSema subgroup insights, a buyback tally and a failed injunction request each carry limited informational weight on their own. The upcoming quarterly report is the next occasion to set all of them against actual financial results. What counts is not the tally of favorable announcements but what they are worth to Novo Nordisk's business — and on that, the court ruling, the 25% subgroup figure and the DKK 11.19bn buyback all stay silent.
Ad
Novo Nordisk Stock: New Analysis - 27 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
